STOCK TITAN

Doximity insider plans 5,000-share sale on NYSE for $354,200

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Doximity, Inc. (DOCS) insider filing notifies a proposed sale of 5,000 common shares through Morgan Stanley Smith Barney with an aggregate market value of $354,200.00, scheduled for 10/10/2025 on the NYSE. The shares were acquired the same day by stock option exercise and paid in cash. The filing also discloses three earlier sales by the same seller totaling 15,000 shares in 07/11/2025, 08/08/2025, and 09/12/2025 with gross proceeds of $300,200.00, $315,000.00, and $352,500.00 respectively.

The signer affirms they are unaware of undisclosed material adverse information and, by submitting Form 144, is complying with Rule 144 notification requirements for proposed resale of restricted or control securities.

Positive

  • Timely compliance with Rule 144 by notifying a proposed sale of 5,000 shares
  • Full disclosure of acquisition method (stock option exercise) and cash payment
  • Broker and exchange identified (Morgan Stanley Smith Barney; NYSE) enabling transparent execution

Negative

  • Ongoing insider selling evidenced by 15,000 shares sold in the prior three months
  • Concentrated short-term disposals may signal continued insider liquidity needs over recent months

Insights

Insider exercised options and plans a sale of 5,000 shares on 10/10/2025.

The filing shows the 5,000 shares were acquired on 10/10/2025 via a stock option exercise with cash payment and are scheduled for sale through Morgan Stanley Smith Barney on the NYSE for an aggregate value of $354,200. This is routine for option holders who exercise and promptly sell to cover tax and cost basis.

Recent prior disposals total 15,000 shares across three dates in 07/11/2025, 08/08/2025, and 09/12/2025, indicating ongoing vesting-related or liquidity-driven sales. Monitor short-term insider liquidity patterns over the next 30-90 days for additional filings.

Form 144 is a procedural disclosure to satisfy Rule 144 resale notice requirements.

The filer affirms the absence of undisclosed material adverse information and provides broker, share count, and aggregate value details required for compliance. The schedule and broker details (Morgan Stanley Smith Barney) align with standard resale channels for registered securities on the NYSE.

Watch for any related Form 4 or amended Form 144s within several days that would confirm execution or changes to the proposed sale.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed for DOCS on 10/10/2025 disclose?

It discloses a proposed sale of 5,000 common shares with aggregate market value $354,200.00, acquired by stock option exercise and to be sold via Morgan Stanley Smith Barney on the NYSE on 10/10/2025.

Who is selling the DOCS shares and how were they acquired?

The filing indicates the shares were acquired by the selling person via a stock option exercise on 10/10/2025 and paid for in cash.

Has the same person sold DOCS shares recently?

Yes. The filing lists three prior sales totaling 15,000 shares on 07/11/2025, 08/08/2025, and 09/12/2025 with combined gross proceeds of $967,700.00.

Does this Form 144 confirm the sale has occurred?

No. Form 144 notifies a proposed sale under Rule 144. Execution would typically be confirmed later by a Form 4 or another filing.

Where will the proposed DOCS shares be sold?

The notice specifies the sale is planned on the NYSE through Morgan Stanley Smith Barney LLC.
Doximity Inc

NYSE:DOCS

DOCS Rankings

DOCS Latest News

DOCS Latest SEC Filings

DOCS Stock Data

7.34B
134.21M
2.29%
90.53%
2.51%
Health Information Services
Services-computer Programming Services
Link
United States
SAN FRANCISCO